Crinetics Pharmaceuticals(CRNX)
SAN DIEGO, CAPharmaceutical
Focus: Crinetics is a public-stage small molecule pharmaceutical company focused on neurology and neuroendocrine disorders, with a recently launched product (Palsonify) and an active pipeline spanning acromegaly, carcinoid syndrome, and adrenal conditions.
Profile data last refreshed 4h ago · AI intelligence enriched 1mo ago
Funding Stage
PUBLIC
Open Jobs
10-3 this month
Stable — net -3 jobs in 30d
8 added, 11 removed. Backfill posture.
Should You Work at Crinetics Pharmaceuticals?
AI assessmentCrinetics is a high-risk, high-science opportunity best suited for early-career researchers or clinicians willing to bet on three Phase 3 programs and a newly launched product in exchange for financial instability and limited company scale.
Why Work Here
- Lead a commercializing product with recent launch momentum—Palsonify generated $10.3M in Q2 2026, signaling early market traction in a niche rare disease space.
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$4M
Key Products
Launch17.6yr
First-in-class somatostatin receptor 2 (SSTR2) agonist with 4000-fold selectivity; generated $10.3M in Q2 2026 post-launch.
Help build intelligence for Crinetics Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.